Intellia Therapeutics Inc
NASDAQ:NTLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
US |
|
DENTSPLY SIRONA Inc
F:DY2
|
US |
|
GSK plc
F:GS71
|
UK |
|
S
|
Southwest Airlines Co
XMUN:SWN
|
US |
|
D
|
Dexcom Inc
XBER:DC4
|
US |
|
Nissan Chemical Corp
TSE:4021
|
JP |
|
E
|
Encompass Health Corp
SWB:HSOA
|
US |
|
D
|
Dexcom Inc
F:DC4
|
US |
|
T
|
Two Harbors Investment Corp
F:2H2A
|
US |
|
M
|
Minth Group Ltd
XBER:M3I
|
CN |
|
Y
|
Yum! Brands Inc
XBER:TGR
|
US |
|
N
|
Nissan Chemical Corp
XMUN:NSC
|
JP |
|
Emperador Inc
XPHS:EMI
|
PH |
|
Industria de Diseno Textil SA
F:IXD1
|
ES |
|
H
|
Halliburton Co
XBER:HAL
|
US |
Wall St Price Targets
NTLA Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
NTLA is 27.26 USD with a low forecast of 9.09 USD and a high forecast of 99.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NTLA's stock price target?
Price Target
27.26
USD
According to Wall Street analysts, the average 1-year price target for
NTLA is 27.26 USD with a low forecast of 9.09 USD and a high forecast of 99.75 USD.
What is the Revenue forecast for Intellia Therapeutics Inc?
Projected CAGR
182%
Over the last 10 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 3 years is 182%.